NCT02030847已完成2 期
Phase II Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or RefractoryAcute Lymphoblastic Leukemia
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Overall Complete Remission Rate at Day 28 After CART-19 Therapy
研究概览
简要总结
This is a single center, single arm, open-label phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Inclusion criteria are designed to include adult patients aged greater than 18 with B cell ALL, relapsed or refractory, with no available curative treatment options (such as autologous or allogeneic stem cell transplantation) who have limited prognosis (greater than 12 weeks survival expectancy) with currently available therapies. The study product is CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 108 transduced CAR T cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form must be obtained prior to any study procedure
- •Relapsed or refractory B-cell ALL
- •1st or greater BM relapse OR
- •Any marrow relapse after allogeneic HSCT and > 100 days from transplant OR
- •For patients with refractory disease:
- •i. < 60 years old that have not achieved a CR after > 2 or more chemotherapy regimens ii. >60 years old that have not achieved a CR after 1 prior chemotherapy regimen d. Patients with Ph+ ALL are eligible if they have failed tyrosine kinase inhibitor therapy
- •Documentation of CD19 tumor expression in bone marrow or peripheral blood by flow cytometry within 3 months of screening.
- •Adequate organ function defined as:
- •Creatinine < 1.6 mg/dl
- •ALT/AST < 3x upper limit of normal range
- •Direct bilirubin <2.0 mg/dl
- •Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea, pulse oxygen > 92% on room air, and DLCO > 40% (corrected for anemia if clinically appropriate)
- •Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA
- •Bone marrow with ≥ 5% lymphoblasts
- •Male or female age ≥ 18 years
- •A ECOG Performance Status that is either 0 or 1
- •No contraindications for leukapheresis.
- •Retreatment Inclusion Criteria
- •Performance Status 0-1
- •Adequate organ system function including:
- •Creatinine < 1.6 mg/dl
- •ALT/AST < 3x upper limit of normal
- •Total Bilirubin < 2.0 mg/dl
- •Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea, pulse oxygen > 92% on room air, and DLCO > 40% (corrected for anemia if clinically appropriate)
- •Left Ventricular Ejection Fraction ≥ 40%
- •No contraindications for leukapheresis (if required for retreatment)
- •Gives voluntary informed consent for retreatment
排除标准
- •Isolated extramedullary disease relapse
- •Active hepatitis B or active hepatitis C
- •Class III/IV cardiovascular disability according to the New York Heart Association Classification
- •HIV infection
- •Active acute or chronic graft-versus-host disease (GVHD) or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment.
- •Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications.
- •Active CNS involvement by malignancy. Note: Patients with history of CNS disease that has been effectively treated will be eligible provided that treatment was >4 weeks before enrollment
- •Pregnant or nursing (lactating) women, female study participants of reproductive potential must have a negative serum or urine pregnancy test within 48 hours before infusion
- •Participation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulation. Participation in non-therapeutic research studies is allowed.
- •Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.
- •Retreatment Exclusion Criteria
- •Pregnant or lactating women.
- •Active hepatitis B or hepatitis C
- •Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid or immunosuppressant medications.
- •HIV infection
- •Patients with active CNS involvement with malignancy. Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was >4 weeks before enrollment on the retreatment cohort.
- •Class III/IV cardiovascular disability according to the New York Heart Association Classification
- •Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.
研究组 & 干预措施
Arm1
Experimental
phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-19" cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
干预措施: CART-19 (Biological)
结局指标
主要结局
Overall Complete Remission Rate at Day 28 After CART-19 Therapy
时间窗: 28 Days
Overall Complete Remission Rate (ORR) which includes complete remission (CR) and CR with incomplete blood count recovery (CRi) at Day 28. Overall Complete Remission Rate = CR+ CRi
次要结局
- Best Overall Response(from the start of the treatment until death, last follow up, relapse or start of new anticancer therapy, whichever comes first, assessed up to 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B CellLymphoma, B-CellSmall Lymphocytic LymphomaLymphoma, Non-HodgkinChronic Lymphocytic LeukemiaNCT03019055Medical College of Wisconsin26
已完成
1 期
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyAdult Acute Lymphoblastic Leukemia in RemissionRecurrent Grade 2 Follicular LymphomaStage III Mantle Cell LymphomaHematopoietic/Lymphoid CancerB-cell Chronic Lymphocytic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaStage III Adult Diffuse Large Cell LymphomaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage IV Adult Diffuse Large Cell LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaRecurrent Grade 1 Follicular LymphomaStage III Chronic Lymphocytic LeukemiaStage III Grade 3 Follicular LymphomaStage IV Chronic Lymphocytic LeukemiaProlymphocytic LeukemiaStage IV Grade 1 Follicular LymphomaNCT01029366University of Pennsylvania26
终止
2 期
CART-19 Post-ASCT for Multiple MyelomaMultiple MyelomaNCT02794246University of Pennsylvania6
Unknown
不适用
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsB Cell LeukemiaAdenocarcinoma of Esophagogastric JunctionB Cell LymphomaMyelomaPancreatic CarcinomaHepatocellular CarcinomaNCT03302403Kang YU18
Unknown
1 期
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaRefractory or Relapsed Multiple MyelomaNCT03716856First Affiliated Hospital of Zhejiang University11